Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market.

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...